Abstract: Circulating tumor DNA (ctDNA), known as an emerging molecular biological technique, plays an increasingly vital role in glioma’s early diagnosis, treatment susceptibility monitoring and individualized treatment plan formulation. The IDH and EGFRvIII mutations, methylation status of promoters of MGMT as well as loss of heterozygosity (LOH) in chromosomes arms 1p, 19q and 10q have become the hot spots of glioma research.

Key words: glioma, circulating tumor DNA, genetic mutation, promoter methylation, loss of heterozygosity